Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst estimates
Biogen shifted its M&A strategy to focus on bolt-on deals after its acquisition of Apellis Pharmaceuticals pushed quarterly revenue above analyst expectations.
Apellis Pharmaceuticals
NASDAQ: APLS ~$3.5B MCAP
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company developing targeted C3 therapies to inhibit the complement cascade in diseases of hematology, ophthalmology, and nephrology. The company has two FDA-approved C3 inhibitors: Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH), and Syfovre for geographic atrophy (GA) secondary to age-related macular degeneration.
Company Info
Sector:Biotechnology / Complement Therapeutics
Headquarters:Waltham, Massachusetts, USA
Founded:2009
Website:apellis.com/
Upcoming Milestones & Key Dates
Q2 2026
Earnings
Q1 2026 Earnings — Syfovre launch trajectory and Empaveli expansion update
Late 2026
Clinical Trial
Potential label expansion data for pegcetacoplan in additional complement indications
Clinical Development Pipeline
Empaveli (pegcetacoplan)
Target: C3 complement inhibitorSyfovre (pegcetacoplan)
Target: C3 complement inhibitor (intravitreal)Pegcetacoplan
Target: C3 complement inhibitorRecent News
Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations
Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations. Reported by BioSpace on 2026-07-29.
Leadership Team
Careers & Job Openings